IRIS
FARINA, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 246
NA - Nord America 201
AS - Asia 94
Totale 541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 201
SE - Svezia 110
IT - Italia 78
CN - Cina 49
SG - Singapore 33
RU - Federazione Russa 26
FI - Finlandia 12
IE - Irlanda 6
DE - Germania 5
PH - Filippine 4
GB - Regno Unito 3
IN - India 3
BE - Belgio 2
FR - Francia 2
IR - Iran 2
JP - Giappone 2
IL - Israele 1
NL - Olanda 1
UA - Ucraina 1
Totale 541
Salva come PNG Salva come JPEG
Città #
Shanghai 35
Ashburn 23
Lawrence 20
Princeton 20
Boardman 17
Milan 17
New York 16
Singapore 15
Moscow 14
Rome 13
Helsinki 12
Ancona 4
Dallas 4
Los Angeles 4
Quezon City 4
Seattle 4
Ballincollig 3
Dublin 3
Osimo 3
Poli 3
Pune 3
San Giuliano 3
Vittoria 3
York 3
Bosco Chiesanuova 2
Castel Mella 2
Dalmine 2
Florence 2
Ghent 2
Honcho 2
Santa Clara 2
Verona 2
Amsterdam 1
Bologna 1
Giv‘atayim 1
Hangzhou 1
Isfahan 1
Modena 1
Nantong 1
Paris 1
San Mateo 1
Shenzhen 1
Trentola-Ducenta 1
Trumbull 1
Turin 1
Washington 1
Weitang 1
Totale 277
Salva come PNG Salva come JPEG
Nome #
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 37
Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia 32
Biobanking for COVID-19 research 28
POS0726 POST-TRAUMATIC STRESS DISORDER AND QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS. A CROSS SECTIONAL WEB SURVEY-BASED STUDY 28
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 27
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 27
Obesity and its role in the management of rheumatoid and psoriatic arthritis 26
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 25
Post-traumatic stress disorder in patients with systemic lupus erythematosus heavily affects quality of life. A cross-sectional web survey-based study 23
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 22
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 22
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 21
Drug retention rates of biological agents in adult onset Still's disease 21
COVID-19: Pharmacology and kinetics of viral clearance 20
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 19
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function 18
Loss of circulating CD8+ CD161high T cells in primary progressive multiple sclerosis 17
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 17
Current treatment options and safety considerations when treating adult-onset Still’s disease 17
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 16
Low prevalence of arrhythmias in clinically stable COVID-19 patients 15
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 14
Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis 14
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 13
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 12
Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle 10
Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year 10
Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort 10
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 8
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 8
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 8
Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature 8
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 7
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 6
Totale 606
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010 0 0 0 0 0 0 0 0 0 2 7 1
2020/202119 1 0 3 1 0 6 4 1 0 0 2 1
2021/202248 1 0 12 14 2 0 1 1 6 7 0 4
2022/2023216 50 43 16 6 12 25 20 25 4 2 6 7
2023/2024242 11 26 32 27 26 28 14 27 0 4 13 34
2024/202571 56 15 0 0 0 0 0 0 0 0 0 0
Totale 606